Klinická farmakologie a farmacie – 1/2021

www.klinickafarmakologie.cz / Klin Farmakol Farm 2021; 35(1): 35–39 / KLINICKÁ FARMAKOLOGIE A FARMACIE 39 FARMAKOLOGICKÝ PROFIL Durvalumab v léčbě nemalobuněčného karcinomu plic after Chemoradiotherapy in Stage III Non‑Small‑Cell Lung Cancer. N. Engl. J. Med. 2017; 377(20): 1919–1929. https://doi. org/10.1056/NEJMoa1709937. 19. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz‑Ares L, Faivre‑Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. Three‑Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC‑Update from PACIFIC. J Thorac Oncol 2020; 15(2): 288–293. https://doi.org/10.1016/j.jtho.2019. 10. 002. 20. Faivre‑Finn C, Vicente D, Kurata T, Planchard D, Paz‑Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu Y‑L, Gray JE, Özgüroğlu M, Lee KH, Newton M, Wang L, Thiyagarajah P, Antonia SJ. LBA49 Dur‑ valumab after Chemoradiotherapy in Stage III NSCLC: 4-Year Survival Update from the Phase III PACIFIC Trial. Annals of Oncology 2020; 31: S1178–S1179. https://doi.org/10.1016/j. annonc.2020. 08. 2281. 21. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, deWit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y‑C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz‑Ares L, de Castro Carpeño J, Faivre‑Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379(24): 2342–2350. https://doi.org/10.1056/NEJMoa1809697. 22. Faivre‑Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz‑Ares L, Poole L, Wadsworth C, Dennis PA, Antonia SJ. 1363OEfficacy and Safety Evaluation Based on Time from Completion of Radiotherapy to Randomization with Durvalumab or Placebo in Pts from PACIFIC. Ann Oncol 2018; 29(suppl_8). https://doi.org/10.1093/annonc/mdy291. 23. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, deWit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y‑C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz‑Ares L, de Castro Carpeño J, Faivre‑Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379(24): 2342–2350. https://doi.org/10.1056/NEJMoa1809697. 24. European Medical Agency. Imfinzi: Summary of Produ‑ ct Characteristics, Https://www.Ema.Europa.Eu/En/Docu‑ ments/Product‑Inf. 25. FDA Approves Additional Dosing Option of Durvalu‑ mab for Stage III NSCLC, Advanced Bladder Cancer https:// www.cancernetwork.com/view/fda‑approves‑additional­ ‑dosing‑option‑of‑durvalumab‑for‑stage‑iii‑nsclc‑advanced­ ‑bladder‑cancer (accessed Nov 29, 2020). 26. Imfinzi‑Epar‑Product‑Information_cs.Pdf. 27. Durm GA, Althouse SK, Sadiq AA, Jalal SI, Jabbour S, Zon R, Kloecker GH, Fisher WB, Reckamp KL, Kio EA, Langdon RM, Adesunloye B, Gentzler RD, Hanna NH. Phase II Trial of Con‑ current Chemoradiation with Consolidation Pembrolizu‑ mab in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14-179. JCO 2018; 36(15_suppl): 8500–8500. https://doi.org/10.1200/ JCO.2018. 36. 15_suppl.8500.